BETAEVAL - The New BETACONNECT Auto-injector: Adherence and EVALuation of MS Patients Treated With Betaferon

Trial Profile

BETAEVAL - The New BETACONNECT Auto-injector: Adherence and EVALuation of MS Patients Treated With Betaferon

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Sep 2016

At a glance

  • Drugs Interferon beta-1b (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms BETAEVAL
  • Sponsors Bayer
  • Most Recent Events

    • 17 Sep 2016 Interim results (n=443) presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
    • 08 Jun 2016 Status changed from recruiting to completed.
    • 27 Jun 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top